Tuesday
BioTech Webinars
Oct. 27th
1
11:00 am – 12:00 pm ET
Where is the growing science and its link to disease leading us in terms of new treatments for patients with unresolved chronic conditions?
Category: Chronic conditions
Chair:
Dr Michael ROSENBLATT M.D.
Chief Medical Officer
Flagship Pioneering, Cambridge, MA
Moderator: Lorem Ipsum, Clinical Research Consultants and HumanOptics AG, Clinical Research Consultants and HumanOptics AG
WHO IS SPEAKING
Representative of
Medicines360
Ponda Motsepe – Ditshego, MD, MBChB, GEDP
Executive Medical Director
Amgen Bone
Representative of
Amgen
Eric M Pearlman
Senior Medical Director-Neuroscience, US Medical Affairs
Eli Lilly and Company
Dan Cua, Ph.D.
Vice President
IL-23 Pathway Area Leader for the Immunology Therapeutic Area
Janssen Biotech, Inc.
Representative of
Novo Nordisk
Representative of
Regeneron and Sanofi
2
12:00 pm – 1:15 pm ET
Can the foundational biologic understandings now being brought to cancer care be leveraged to secure a targeted, more personalized approach to other conditions?
Category: Cancer, other rare conditions and vaccines
Moderator: Lorem Ipsum, Clinical Research Consultants and HumanOptics AG, Clinical Research Consultants and HumanOptics AG
Moderator: Lorem Ipsum, Clinical Research Consultants and HumanOptics AG, Clinical Research Consultants and HumanOptics AG
WHO IS SPEAKING
Javad Shahidi, MD, MSc
Vice President, Global Oncology R&D
Daiichi Sankyo
Beth-Ann Coller, Ph.D.
Executive Director, Global Clinical Development
Merck & Co., Inc
Representative of
Dompé U.S. Inc.
Representative of
Takeda Pharmaceutical Company Limited
Bernard Delaey
Regulatory Therapeutic Area Lead
Sanofi
Representative of
Genentech, a member of the Roche Group
3
1:30 pm – 2:45 pm ET
Will progress in therapies that promise a genetic cure for devastating rare diseases lead to similar innovations in patient access to these highcost, high-touch treatments?
Category: Rare Genetic Disorders
Chair:
Pr Mary-Claire KING
American Cancer Society Professor of Genome Sciences and Medical Genetics
University of Washington
Moderator: Lorem Ipsum, Clinical Research Consultants and HumanOptics AG, Clinical Research Consultants and HumanOptics AG
WHO IS SPEAKING
Representative of
Akcea Therapeutics and Ionis Pharmaceticals
Pushkal Garg, MD
Chief Medical Officer
Alnylam
Representative of
BioMarin Pharmaceutical, Inc.
Ted W. Love, M.D.
President & Chief Executive Officer
Global Blood Therapeutics, Inc.
Petra Kaufmann, M.D.
Senior Vice President, Translational Medicine and Clinical Development
Novartis Gene Therapies
